Clinical trials: Mild Hemophilia

Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

• Completed
• Age: All ages
• Phase 3
• Injection or infusion
• Results posted

This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against…

Conditions

Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A

Trial name

HAVEN 6 (NCT04158648)

Testing

Emicizumab

Where

22 sites in United States, Belgium and 8 more

Volunteers

73 people

Sponsor

Hoffmann-La Roche